Vascular Biogenics

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Notable Labs Ltd. is a clinical-stage platform therapeutics company that develops predictive medicines for patients with cancer. Through its proprietary Predictive Medicines Platform, the firm predicts whether or not that patient is likely to respond to that specific therapeutic. The company's Predictive Medicines Platform is designed to identify and select patients expected to be clinically responsive prior to their treatment to improve patient outcomes and fast-track clinical development. The firm's product candidate, Volasertib, is a Polo-like Kinase 1 inhibitor. Notable Labs was founded on January 31, 2000 and is headquartered in Foster City, CA.

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -9.09% and 220.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Vascular Biogenics (VBLT) Reports Q3 Loss, Tops Revenue Estimates

Continued progress on previously announced strategic process to maximize shareholder value Continued progress on previously announced strategic process to maximize shareholder value

VBL Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

TEL AVIV, Israel and NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), a biotechnology company developing targeted medicines for immune-inflammatory diseases, today announced that VBL received a written notification (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) on August 31, 2022, notifying VBL that it is not in compliance with the minimum bid price requirement set forth in the Nasdaq Listing Rules for continued listing on the Nasdaq.

VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 7.69% and 57.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Vascular Biogenics (VBLT) Reports Q2 Loss, Misses Revenue Estimates

Exploring strategic options to maximize shareholder value; engaged Chardan as financial advisor Exploring strategic options to maximize shareholder value; engaged Chardan as financial advisor

VBL Therapeutics Announces Second Quarter 2022 Financial Results and Corporate Process to Explore Strategic Options

Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Vascular Biogenics (VBLT) to Report a Decline in Earnings: What to Look Out for

TEL AVIV, Israel and NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a biotechnology company developing targeted medicines for cancer and immune-inflammatory diseases, today announced an organizational streamlining designed to reduce operating expenses and preserve capital. As a result, VBL will reduce its workforce by approximately 35%. As part of the cost cutting initiatives, Dr. Ron Cohen, Dr. Bennett Shapiro and Ms. Alison Finger resigned from the board of directors, effective August 1, 2022.

VBL Therapeutics Announces Workforce Reduction

Vascular Biogenics' (VBLT) phase III OVAL study, evaluating ofra-vec in patients with platinum-resistant ovarian cancer, fails to meet the primary endpoint.

Vascular Biogenics (VBLT) Down, Ovarian Cancer Study Fails

The selling pressure on VBLT stock is heavy today as Vascular Biogenics releases the clinical trial results for its ovarian cancer treatment. The post Why Is Vascular Biogenics (VBLT) Stock Down 80% Today?

Why Is Vascular Biogenics (VBLT) Stock Down 80% Today?

Vascular Biogenics Ltd (NASDAQ: VBLT) shares are falling Wednesday after the company announced that the data from its Phase 3 OVAL trial of ofra-vec in platinum-resistant ovarian cancer did not meet the primary endpoints. Vascular Biogenics said the trial did not achieve a.

Why Vascular Biogenics Stock Is Plunging

- Trial Did Not Meet Statistical Significance on Improvement in Primary Endpoints of Progression Free Survival (PFS) or Overall Survival (OS) - - Trial Did Not Meet Statistical Significance on Improvement in Primary Endpoints of Progression Free Survival (PFS) or Overall Survival (OS) -

VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer

TEL AVIV, Israel and NEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics, will present a corporate overview and participate in investor meetings at the upcoming Jefferies Healthcare Conference being held in New York on June 8 – 10, 2022.

VBL Therapeutics to Participate in the Jefferies Healthcare Conference

Vascular Biogenics Ltd. (NASDAQ:VBLT ) Q1 2022 Earnings Conference Call May 17, 2022 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors, IR Dror Harats - CEO Sam Backenroth - CFO Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Kevin DeGeeter - Oppenheimer RK Ramakanth - H.C.

Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q1 2022 Results - Earnings Call Transcript

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -8.33% and 42.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Vascular Biogenics (VBLT) Reports Q1 Loss, Misses Revenue Estimates

OVAL Phase 3 top-line data expected in 2H 2022; with positive results, VBL anticipates submitting a BLA to the FDA in 1H 2023

VBL Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

TEL AVIV, Israel and NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that it will release first quarter financial results for the period ended March 31, 2022 on Tuesday, May 17 before market open. Professor Dror Harats, M.D, Chief Executive Officer, and Sam Backenroth, Chief Financial Officer, will host a conference call at 8:30am ET to discuss the results and provide a corporate update.

VBL Therapeutics to Report First Quarter 2022 Financial Results on May 17

TEL AVIV, Israel and NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that the company will present new data on its novel Monocyte Targeting Technology and lead candidate VB-601 at IMMUNOLOGY2022TM being held in Portland, OR on May 6 – 10, 2022. In addition, Dror Harats, M.D., Chief Executive Officer of VBL Therapeutics, will discuss the VB-601 program at the LifeSci Immunology & Inflammation Symposium being held virtually on May 11, 2022. Prof. Harats will also provide a keynote presentation at the Biomed Israel 2022 Conference on May 12, 2022, and a corporate overview at the H.C. Wainwright Global Investment Conference taking place May 23 – May 26, 2022.

VBL Therapeutics to Participate in Upcoming Scientific and Industry Conferences in May

TEL AVIV, Israel and NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that the Compensation Committee of VBL's Board of Directors approved the grant effective April 24, 2022 of a non-qualified stock option to purchase an aggregate of 75,000 ordinary shares of VBL as an inducement material to the hiring of a new employee, in accordance with Nasdaq Listing Rule 5635(c)(4).

VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

TEL AVIV, Israel and NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ofra-vec (ofranergene obadenovec or VB-111) in combination with paclitaxel for the treatment of platinum-resistant ovarian cancer.

VBL Therapeutics Receives FDA Fast Track Designation for Ofra-Vec for the Treatment of Platinum-Resistant Ovarian Cancer

Three leading experts in gynecological oncology will discuss treatment landscape and unmet needs in ovarian cancer

VBL Therapeutics to Host In-Person Key Opinion Leader Seminar on Ovarian Cancer

Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q4 2021 Results - Earnings Call Transcript

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -50% and 2%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Vascular Biogenics (VBLT) Reports Q4 Loss, Lags Revenue Estimates

TEL AVIV, Israel and NEW YORK, March 23, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant and solid tumors and immune or inflammatory indications, today announced financial results for the fiscal year ended December 31, 2021, and provided a corporate update.

VBL Therapeutics Reports Full Year 2021 Financial Results and Provides Corporate Update

TEL AVIV, Israel and NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that it will release financial results for the year ended December 31, 2021 on Wednesday, March 23 before market open. Professor Dror Harats, M.D., Chief Executive Officer, and Sam Backenroth, Chief Financial Officer, will host a conference call at 8:30am ET to discuss the results and provide a corporate update.

News for Vascular Biogenics Stock (VBLT)